Could two years really have made the difference? While some healthcare reforms proposals have called for raising Medicare eligibility from age 65 to 67 to address cost concerns associated with the Affordable Care Act, President Obama has made it clear that he would not consider increasing the age limit as a way to aid the national deficit.
Could two years really have made the difference? While some healthcare reforms proposals have called for raising Medicare eligibility from age 65 to 67 to address cost concerns associated with the Affordable Care Act, President Obama has made it clear that he would not consider increasing the age limit as a way to aid the national deficit. Jay Carney, Whitehouse spokesperson, recently stated in a press briefing that “the President has made clear that we don’t believe that that’s the right policy to take.”
A 2011 Kaiser Family Foundation study reported that, if the government raised the Medicare eligibility age to 67 in 2014, it could save the federal government an estimated $5.7 billion. However, the foundation also reported that raising the age could potentially cost some groups of seniors as much as $3.7 billion, and another $4.5 billion in employer retiree funds. President Obama said that he would consider other entitlement reforms to reduce the federal deficit—including those for Social Security and government pension programs—in order to avoid burdening seniors from receiving proper healthcare, and even went so far as to volunteer 5% of his salary toward the national deficit for each month furloughed government workers face unpaid work leave.
The Washington Post’s Ezra Klein reported that the change in Medicare eligibility was likely rejected because the potential benefits in resolving deficit issues through an increase, are no longer available. Klein stated that “the cutoff for Medicare eligibility age has been under consideration repeatedly, giving healthcare experts more time to run the numbers and parse their results. Their conclusion, essentially, was that raising the Medicare eligibility age is counterproductive: It cuts the deficit but raises national health spending as it moves seniors to more expensive insurance options.”
Like any other healthcare reform debate, the Medicare age eligibility discussion has many variables. As is so often the case, one decision to help “solve” a problem has the potential to create twice as many. For the time being, it doesn’t appear as though there is enough data or preparedness to make a Medicare age eligibility change.
Around the Web
Why the White House Took the Medicare Age off the Table [Washington Post]
Raising the Age of Medicare Eligibility: A Fresh Look Following Implementation of Health Reform [Kaiser Family Foundation]
Obama’s Voluntary 5% Pay Cut Joined by Lew, Kerry, Holder [Bloomberg]
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More